Background: Despite several clinical trials and advances in understanding the genetic basis
of biliary tract cancer (BTC), the addition of epidermal growth factor receptor (EGFR) …

Cholangiocarcinoma (CCA) is a rare and aggressive type of malignant tumor. In the past few
years, there has been an increase in the incidence of CCA. Surgery is the only effective …

Importance Gemcitabine with platinum has limited efficacy for treatment of advanced
cholangiocarcinoma, necessitating an evaluation of alternative drug combinations. Recent …

Vandetanib did not demonstrate any superiority alone or in combination with gemcitabine in
the progression-free survival of patients affected by advanced biliary tract cancer compared …

Gemcitabine plus cisplatin remains the standard first-line systemic therapy for advanced
cholangiocarcinoma and offers a median survival of approximately 1 year. No standard …

Biliary tract carcinoma is a collective term for a group of rare gastrointestinal cancers. This
overview outlines the key pathways and specialised therapeutics in biliary cancer and the …

Background: Biliary Tract Cancers (BTC) are rare malignancies with a poor prognosis. There
are many challenges encountered in treating these patients in daily practice as well as in …

Abstract Background: Cholangiocarcinomas (CCAs) are aggressive malignancies that
display features of biliary differentiation. According to their anatomical location, CCAs are …

Biliary tract cancers (BTCs) represent a heterogeneous group that includes intrahepatic
cholangiocarcinomas (CCAs), perihilar-CCAs or Klatskin tumors, extrahepatic-CCAs, and …

Biliary tract cancer, or cholangiocarcinoma, comprises a heterogeneous group of malignant
tumors that can emerge at any part of the biliary tree. This group is the second most common …